Want to see GB:GENF full AI Analyst Report?
GENF Stock Chart & Stats
2.05 p
0.00 p(0.00%)
At close: 4:00 PM EDT
2.05 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range0.90 p - 3.12 p
Previous CloseN/A
Volume3.08M
Average Volume (3M)2.39M
Market Cap
£11.19M
Enterprise Value11.17 p
Total Cash (Recent Filing)£111.79K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.12
Next Earnings
Apr 28, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding566,409,800
10 Day Avg. Volume3,528,025
30 Day Avg. Volume2,392,971
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-14.33
Price to Sales (P/S)0.00
P/FCF Ratio-5.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of financial debt reduces refinancing exposure and avoids interest obligations that could further pressure a research-stage company. This provides some financial flexibility, although the benefit is moderated by negative equity and the need to fund ongoing operations.
Improving Free Cash FlowFree cash flow improved year over year, indicating some progress in the pace of cash consumption even though it remains meaningfully negative. If sustained, better cash-flow performance could extend funding runway and reduce the urgency of external capital needs.
Some Improvement In Net LossesThe reduction in net losses provides a modest sign of operating improvement within an otherwise early-stage profile. Continued progress could support eventual cost discipline and better earnings quality, though the company remains pre-revenue and has not established a path to profitability.
Bears Say
Pre-revenue Business ModelWith no reported revenue across the available years, the company has not yet demonstrated commercial product adoption or recurring sales. Persistent operating losses mean future value depends heavily on successful development and eventual commercialization of its research programs.
Negative Shareholders’ EquityThe shift into increasingly negative shareholders’ equity shows that accumulated losses have overwhelmed the capital base. This weakens balance-sheet resilience, limits internal financial flexibility, and increases the importance of raising capital to support continued development activities.
Persistent Cash BurnMulti-year negative operating and free cash flow demonstrates that the business cannot currently fund operations from internally generated cash. Continued burn creates dependence on external funding, potentially diluting shareholders or constraining the pace of research investment.
Genflow Biosciences Plc News
GENF FAQ
What was Genflow Biosciences Plc’s price range in the past 12 months?
Genflow Biosciences Plc lowest share price was 0.90 p and its highest was 3.12 p in the past 12 months.
What is Genflow Biosciences Plc’s market cap?
Genflow Biosciences Plc’s market cap is £11.19M.
When is Genflow Biosciences Plc’s upcoming earnings report date?
Genflow Biosciences Plc’s upcoming earnings report date is Apr 28, 2027 which is in 210 days.
How were Genflow Biosciences Plc’s earnings last quarter?
Genflow Biosciences Plc released its earnings results on Sep 29, 2026. The company reported -0.001 p earnings per share for the quarter.
Is Genflow Biosciences Plc overvalued?
According to Wall Street analysts Genflow Biosciences Plc’s price is currently Overvalued.
Does Genflow Biosciences Plc pay dividends?
Genflow Biosciences Plc does not currently pay dividends.
What is Genflow Biosciences Plc’s EPS estimate?
Genflow Biosciences Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genflow Biosciences Plc have?
Genflow Biosciences Plc has 566,409,800 shares outstanding.
What happened to Genflow Biosciences Plc’s price movement after its last earnings report?
Genflow Biosciences Plc reported an EPS of -0.001 p in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Genflow Biosciences Plc?
Currently, no hedge funds are holding shares in GB:GENF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genflow Biosciences Plc
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the fibroblasts in the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, which addresses mitochondrial dysfunction observed in sarcopenia for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was founded in 2020 and is headquartered in London, the United Kingdom.
Technical Analysis
Oxford BioDynamics
―
Physiomics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―